399 related articles for article (PubMed ID: 32265117)
1. The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial.
Wang J; Fan J; Li C; Yang L; Wan J; Zhang H; Zhang Z; Zhu J
Clin Colorectal Cancer; 2020 Jun; 19(2):e58-e69. PubMed ID: 32265117
[TBL] [Abstract][Full Text] [Related]
2. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by
Zhu J; Liu A; Sun X; Liu L; Zhu Y; Zhang T; Jia J; Tan S; Wu J; Wang X; Zhou J; Yang J; Zhang C; Zhang H; Zhao Y; Cai G; Zhang W; Xia F; Wan J; Zhang H; Shen L; Cai S; Zhang Z
J Clin Oncol; 2020 Dec; 38(36):4231-4239. PubMed ID: 33119477
[TBL] [Abstract][Full Text] [Related]
4. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
Kimura K; Yamano T; Igeta M; Imada A; Jihyung S; Babaya A; Hamanaka M; Kobayashi M; Tsukamoto K; Noda M; Ikeda M; Tomita N
Cancer Sci; 2018 Dec; 109(12):3934-3942. PubMed ID: 30246377
[TBL] [Abstract][Full Text] [Related]
5. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
Zhu J; Li X; Shen Y; Guan Y; Gu W; Lian P; Sheng W; Cai S; Zhang Z
Radiother Oncol; 2018 Oct; 129(1):143-148. PubMed ID: 29273261
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer.
Kawai K; Sunami E; Hata K; Tanaka T; Nishikawa T; Otani K; Sasaki K; Nozawa H
Clin Colorectal Cancer; 2018 Sep; 17(3):240-246. PubMed ID: 29934092
[TBL] [Abstract][Full Text] [Related]
7. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
8. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
[TBL] [Abstract][Full Text] [Related]
9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
10. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
11. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Sato T; Hayakawa K; Tomita N; Noda M; Kamikonya N; Watanabe T; Kato D; Sakai Y; Hiraoka M; Shimada M; Ikushima H; Baba H; Oya N; Oya M; Nemoto-Murofushi K; Takeuchi M; Watanabe M
Radiother Oncol; 2016 Aug; 120(2):222-7. PubMed ID: 27317556
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
14. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer.
Ren DL; Li J; Yu HC; Peng SY; Lin WD; Wang XL; Ghoorun RA; Luo YX
World J Gastroenterol; 2019 Jan; 25(1):118-137. PubMed ID: 30643363
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
16. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
18. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
20. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]